Tesamorelin: The FDA-Approved GHRH Analog Targeting Visceral Fat and Metabolic Dysfunction
A synthetic analog of growth hormone-releasing hormone approved by the FDA for HIV-associated lipodystrophy, Tesamorelin reduces visceral fat through targeted stimulation of the pituitary GH axis — with emerging research exploring its role in metabolic health and cognitive aging.